Equities analysts predict that Inovio Pharmaceuticals Inc (NASDAQ:INO) will post ($0.32) earnings per share for the current quarter, Zacks reports. Three analysts have made estimates for Inovio Pharmaceuticals’ earnings. The highest EPS estimate is ($0.31) and the lowest is ($0.33). Inovio Pharmaceuticals posted earnings of ($0.40) per share in the same quarter last year, which indicates a positive year over year growth rate of 20%. The business is scheduled to report its next quarterly earnings results on Wednesday, November 14th.
According to Zacks, analysts expect that Inovio Pharmaceuticals will report full-year earnings of ($1.06) per share for the current fiscal year, with EPS estimates ranging from ($1.09) to ($1.04). For the next year, analysts forecast that the firm will report earnings of ($1.09) per share, with EPS estimates ranging from ($1.25) to ($0.94). Zacks Investment Research’s earnings per share calculations are an average based on a survey of research firms that follow Inovio Pharmaceuticals.
Inovio Pharmaceuticals (NASDAQ:INO) last posted its earnings results on Tuesday, August 7th. The biopharmaceutical company reported ($0.08) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.35) by $0.27. The firm had revenue of $24.45 million for the quarter, compared to the consensus estimate of $2.13 million. Inovio Pharmaceuticals had a negative net margin of 252.95% and a negative return on equity of 71.53%.
Several equities analysts have commented on the stock. BidaskClub raised shares of Inovio Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Wednesday, September 12th. ValuEngine raised shares of Inovio Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, September 5th. HC Wainwright set a $13.00 target price on shares of Inovio Pharmaceuticals and gave the stock a “buy” rating in a research report on Tuesday. Stifel Nicolaus assumed coverage on shares of Inovio Pharmaceuticals in a research report on Tuesday, October 2nd. They set a “buy” rating and a $8.00 target price on the stock. Finally, Maxim Group reissued a “buy” rating and set a $8.00 target price on shares of Inovio Pharmaceuticals in a research report on Thursday, August 16th. Three equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $10.75.
In other Inovio Pharmaceuticals news, CEO Jong Joseph Kim sold 49,060 shares of the company’s stock in a transaction dated Wednesday, September 12th. The shares were sold at an average price of $5.37, for a total transaction of $263,452.20. Following the completion of the sale, the chief executive officer now directly owns 2,357,554 shares in the company, valued at $12,660,064.98. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 9.40% of the stock is owned by corporate insiders.
A number of hedge funds have recently added to or reduced their stakes in the business. Swiss National Bank lifted its stake in shares of Inovio Pharmaceuticals by 12.8% in the first quarter. Swiss National Bank now owns 156,400 shares of the biopharmaceutical company’s stock valued at $737,000 after buying an additional 17,700 shares during the period. Schwab Charles Investment Management Inc. lifted its stake in shares of Inovio Pharmaceuticals by 23.1% in the first quarter. Schwab Charles Investment Management Inc. now owns 412,279 shares of the biopharmaceutical company’s stock valued at $1,942,000 after buying an additional 77,277 shares during the period. New York State Common Retirement Fund lifted its stake in shares of Inovio Pharmaceuticals by 14.3% in the first quarter. New York State Common Retirement Fund now owns 146,243 shares of the biopharmaceutical company’s stock valued at $689,000 after buying an additional 18,300 shares during the period. UBS Group AG lifted its stake in shares of Inovio Pharmaceuticals by 156.7% in the first quarter. UBS Group AG now owns 442,893 shares of the biopharmaceutical company’s stock valued at $2,086,000 after buying an additional 270,373 shares during the period. Finally, Guggenheim Capital LLC bought a new stake in shares of Inovio Pharmaceuticals in the first quarter valued at about $2,375,000. Institutional investors own 31.52% of the company’s stock.
Inovio Pharmaceuticals stock opened at $5.29 on Friday. The firm has a market cap of $508.72 million, a price-to-earnings ratio of -4.85 and a beta of 1.74. Inovio Pharmaceuticals has a one year low of $3.64 and a one year high of $6.43.
Inovio Pharmaceuticals Company Profile
Inovio Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops active DNA immunotherapies and vaccines to prevent and treat cancers and infectious diseases. Its SynCon immunotherapy design has the ability to break the immune system's tolerance of cancerous cells, as well as is intended to facilitate cross-strain protection against known, as well as new unmatched strains of pathogens, such as influenza.
Featured Story: What is Considered a Good Return on Equity (ROE)?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Inovio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.